Edition:
United Kingdom

Kyorin Holdings Inc (4569.T)

4569.T on Tokyo Stock Exchange

2,180JPY
17 Nov 2017
Change (% chg)

¥-6 (-0.27%)
Prev Close
¥2,186
Open
¥2,189
Day's High
¥2,193
Day's Low
¥2,172
Volume
140,200
Avg. Vol
209,770
52-wk High
¥2,700
52-wk Low
¥2,136

Latest Key Developments (Source: Significant Developments)

KYORIN Holdings unit grants MSD K.K. manufacturing and marketing rights for medicine of allergic diseases
Wednesday, 28 Sep 2016 

KYORIN Holdings Inc <4569.T>:Says MSD K.K. received a manufacturing and marketing approval for DESALEX® Tablets 5mg for the treatment of allergic diseases from the co's unit KYORIN Pharmaceutical Co., Ltd..  Full Article

Kaken Pharmaceutical to co-promote allergic medicine with Kyorin Holdings unit
Monday, 11 Jul 2016 

Kaken Pharmaceutical Co Ltd <4521.T>:Says the company entered into basic agreement with Kyorin Holdings Inc <4569.T>'s unit on co-promotion of an allergic medicine, whose exclusive sales right is owned by the Kyorin Holdings's unit.  Full Article

KYORIN Holdings unit to sign exclusive distribution agreement
Wednesday, 25 May 2016 

KYORIN Holdings Inc <4569.T>:Says company MSD to grant subsidiary KYORIN Pharmaceutical an exclusive distribution license for an allergic disease treatment drug in Japan changed from joint marketing.  Full Article

Kyorin and Kissei sign agreement for co-development and co-marketing of KRP-114V
Wednesday, 30 Mar 2016 

Kyorin Holdings Inc:KYORIN Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. and Kissei Pharmaceutical Co., Ltd. jointly announced a co-development and co-marketing agreement for an overactive bladder medication of KRP-114V (INN: Vibegron) which is being developed by Kyorin in Japan.  Full Article

Kyorin Holdings expects extraordinary loss for FY 2016
Tuesday, 23 Feb 2016 

Kyorin Holdings Inc:Says it expects an extraordinary loss of 2.7 billion yen for FY ending March 2016.Says the loss is recorded for the close of pharmaceutical factory.  Full Article

Kyorin Holdings amends consolidated full-year outlook for FY 2016
Wednesday, 3 Feb 2016 

Kyorin Holdings Inc:Says the company amended the consolidated full-year outlook for the FY ended March 2016.Confirmed the revenue at 120,200 million yen.Operating profit forecast increased to 19,400 million yen from 16,000 million yen.Ordinary profit forecast increased to 19,700 million yen from 16,300 million yen.Net profit forecast increased to 13,000 million yen from 11,500 million yen.Earnings per share forecast increased to 175.39 yen from 155.51 yen.Says license agreement and extraordinary profit are the main reasons for the forecast.  Full Article

Kyorin Holdings announces cancellation of license regarding KRP-AB1102F
Wednesday, 3 Feb 2016 

Kyorin Holdings Inc:Subsidiary KYORIN Pharmaceutical Co., Ltd resolved to cancel license agreement with AstraZeneca UK Limited regarding COPD therapeutic KRP-AB1102F.  Full Article

R&I affirms Kyorin Holdings's rating at "A-" and announces stable outlook
Tuesday, 26 Jan 2016 

Kyorin Holdings Inc:R&I affirms Kyorin Holdings's rating at "A-" and announces stable outlook.  Full Article

Kyorin Holdings subsidiary KYORIN Pharmaceutical signs license agreement with Bristol-Myers Squibb
Wednesday, 9 Dec 2015 

Kyorin Holdings Inc:Subsidiary KYORIN Pharmaceutical Co., Ltd signs license agreement with Bristol-Myers Squibb, on Formyl peptide receptor program.Says the subsidiary granted Bristol-Myers Squibb exclusive development, manufacturing, marketing and sales rights.Subsidiary to receive upfront $35 mln and royalty as well as milestone payments.  Full Article

BRIEF- Kyorin Holdings to set up drug unit in Tokyo

* Says it will set up a wholly owned drug unit in Tokyo, on Oct. 2